These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Is there a role for pharmacoeconomics in developing countries? Harper JR Pharmacoeconomics; 2011 May; 29(5):435-6; author reply 436-7. PubMed ID: 21504243 [No Abstract] [Full Text] [Related]
26. The emerging government requirement for economic evaluation of pharmaceuticals. Drummond M Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586 [TBL] [Abstract][Full Text] [Related]
27. What is next for pharmacoeconomics and outcomes research in Asia? Doherty J; Kamae I; Lee KK; Li H; Li SC; Liu GG; Tarn YH; Yang BM Value Health; 2004; 7(2):118-32. PubMed ID: 15164802 [TBL] [Abstract][Full Text] [Related]
28. The effect of pharmacoeconomics on company research and development decisions. Grabowski H Pharmacoeconomics; 1997 May; 11(5):389-97. PubMed ID: 10168028 [TBL] [Abstract][Full Text] [Related]
29. Emerging role of pharmacoeconomics in the research and development decision-making process. DiMasi JA; Caglarcan E; Wood-Armany M Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911 [TBL] [Abstract][Full Text] [Related]
31. The role of pharmacoeconomics in current Indian healthcare system. Ahmad A; Patel I; Parimilakrishnan S; Mohanta GP; Chung H; Chang J J Res Pharm Pract; 2013 Jan; 2(1):3-9. PubMed ID: 24991597 [TBL] [Abstract][Full Text] [Related]
32. Pharmacoeconomics and formulary decision making. Sanchez LA Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112 [TBL] [Abstract][Full Text] [Related]
33. Value-Based Pricing in Latin America: How Far Away Are We? Mejía A; Gilardino R; Kristensen FB; Garrison LP; Value Health Reg Issues; 2018 Dec; 17():219-223. PubMed ID: 30528780 [TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical economics and health policy research using administrative data. Lyles A Clin Ther; 2004 Jul; 26(7):1122-3. PubMed ID: 15336477 [No Abstract] [Full Text] [Related]
35. Cost-effectiveness analysis: from science to application. Berger ML; Teutsch S Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009 [TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomics and macular degeneration. Brown GC; Brown MM; Brown H; Godshalk AN Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427 [TBL] [Abstract][Full Text] [Related]
37. Value-Based Medicine and Pharmacoeconomics. Brown GC; Brown MM Dev Ophthalmol; 2016; 55():381-90. PubMed ID: 26501688 [TBL] [Abstract][Full Text] [Related]
38. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]